Breast cancer classification and prognosis based on gene expression profiles from a population-based study

By C. Sotiriou, S. Neo, Lisa M. McShane, Edward L. Korn, Philip M. Long, A. Jazaeri, P. Martiat, S. Fox, Adrian L. Harris, E. Liu. Proceedings of the National Academy of Sciences of the United States of America, 2003

2,085 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/58d9e780b459f0336f15ac28a8c6c68ec158b349

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype (2005, background): “However, there are data to indicate that even basal cancers are heterogeneous at a genomic level and that there may be subsets with very poor as well as very good outcomes ( 26 , 27).”
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer (2008, background): “The intrinsic breast cancer genes are 534 genes used to define the molecular subtypes reported by Perou and colleagues (20).”
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. (2004, background): “, 2001, ratio test in a microarray data set containing 45 patients with ER breast cancer treated with tamoxifen monotherapy (Soti2003; Sotiriou et al., 2003; van de Vijver et al., 2002).”
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. (2009, background): “At least six distinct subtypes have been described on the basis of gene expression profiling, with the most important determinants of these subtypes being the presence or absence of expression of the estrogen receptor (ER) or the progesterone receptor (PgR), or the amplification/overexpression of th”
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (2005, background): “Molecular classification n [% (95% CI)] n [% (95% CI)] Luminal A/B subtype 28 [93% (78-99)] 2 [7% (1-22)] Normal breast like 10 [100% (29-100)] 0 [0% (0-31)]”
Biological determinants of endocrine resistance in breast cancer (2009, background): “Differential sensitivity to endocrine therapy is observed in the different subtypes of ER-positive breast cancer that are defined by common patterns of gene expressio”
Breast cancer prognostic classification in the molecular era: the role of histological grade (2010, background): “Th e introduction of high-throughput technologies that survey thousands of genes and their products in a single assay, coupled with powerful analytical tools, has opened up new avenues for classifying breast cancer into biologically and clinically distinct groups based on gene expression patterns [1”